Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: A randomized controlled trial

Kok Min Seow, Yu Hung Lin, Chyi Huey Bai, Heng Ju Chen, Bih Chwen Hsieh, Lee Wen Huang, Chii Ruey Tzeng, Jiann Loong Hwang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cabergoline, a dopamine receptor-2 agonist, is suggested to prevent ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation. The aim of this study was to evaluate the influence of different timing of cabergoline administration on clinical outcome among patients at risk of developing OHSS. Among infertile women undergoing IVF treatment at risk of developing OHSS, 206 were enrolled in this study. The subjects were randomly allocated into two groups, i.e. the study group (n = 100) receiving cabergoline beginning on the day of human chorionic gonadotrophin (HCG) injection and the control group (n = 100) receiving cabergoline starting on the day of oocyte retrieval. Oocyte metaphase-II rate, fertilization rate, clinical outcome and incidence of severe OHSS were compared between the two groups. There were no significant differences in oocyte metaphase-II rate (0.86 ± 0.16 versus 0.85 ± 0.15) or fertilization rate (0.79 ± 0.22 versus 0.76 ± 0.20) or in the incidence of OHSS between two groups. Similarly, there were no significant differences in implantation or clinical pregnancy rate between the two groups. Cabergoline can be administered as soon as HCG injection to prevent early OHSS, without adverse effects on oocyte maturation, fertilization rate and clinical outcome. Cabergoline, a dopamine receptor-2 agonist, is suggested to prevent ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation. Nevertheless, the most suitable timing of cabergoline administration has not yet been studied. The aim of this study was to evaluate the influence of different timing of cabergoline administration on final oocyte maturation, fertilization rate and clinical outcome among patients at risk of developing OHSS. Among infertile women undergoing IVF treatment at risk of developing OHSS, 206 were enrolled in this study. The subjects were randomly allocated into two groups, i.e. the study group (n = 100) receiving cabergoline beginning on the day of human chorionic gonadotrophin (HCG) injection and the control group (n = 100) receiving cabergoline starting on the day of oocyte retrieval. Oocyte metaphase II rate, fertilization rate, clinical outcome and incidence of severe OHSS were compared between the two groups. There were no significant differences in oocyte metaphase II rate (0.86 ± 0.16 versus 0.85 ± 0.15) or fertilization rate (0.79 ± 0.22 versus 0.76 ± 0.20) or in the incidence of OHSS (3/100 versus 1/100) between the control and study groups. Similarly, there were no significant differences in implantation rate (36.6% versus 34.0%) or clinical pregnancy rate (54.0% versus 51.0%) between the two groups. Among women at high risk of OHSS, cabergoline can be administered as soon as the HCG injection to prevent early OHSS, without adverse effects on oocyte maturation, fertilization rate and clinical outcome.

Original languageEnglish
Pages (from-to)562-568
Number of pages7
JournalReproductive BioMedicine Online
Volume26
Issue number6
DOIs
Publication statusPublished - 2013

Fingerprint

Ovarian Hyperstimulation Syndrome
Randomized Controlled Trials
Fertilization
Oocytes
Chorionic Gonadotropin
Metaphase
Oocyte Retrieval
Injections
Ovulation Induction
Incidence
Dopamine Agonists
Pregnancy Rate
cabergoline
Control Groups

Keywords

  • cabergoline
  • fertilization rate
  • metaphase-II rate
  • oocyte maturation
  • ovarian hyperstimulation syndrome
  • pregnancy rate

ASJC Scopus subject areas

  • Reproductive Medicine
  • Developmental Biology

Cite this

Clinical outcome according to timing of cabergoline initiation for prevention of OHSS : A randomized controlled trial. / Seow, Kok Min; Lin, Yu Hung; Bai, Chyi Huey; Chen, Heng Ju; Hsieh, Bih Chwen; Huang, Lee Wen; Tzeng, Chii Ruey; Hwang, Jiann Loong.

In: Reproductive BioMedicine Online, Vol. 26, No. 6, 2013, p. 562-568.

Research output: Contribution to journalArticle

Seow, Kok Min ; Lin, Yu Hung ; Bai, Chyi Huey ; Chen, Heng Ju ; Hsieh, Bih Chwen ; Huang, Lee Wen ; Tzeng, Chii Ruey ; Hwang, Jiann Loong. / Clinical outcome according to timing of cabergoline initiation for prevention of OHSS : A randomized controlled trial. In: Reproductive BioMedicine Online. 2013 ; Vol. 26, No. 6. pp. 562-568.
@article{a0440b38684c4a07b4a22f32aa1eed61,
title = "Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: A randomized controlled trial",
abstract = "Cabergoline, a dopamine receptor-2 agonist, is suggested to prevent ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation. The aim of this study was to evaluate the influence of different timing of cabergoline administration on clinical outcome among patients at risk of developing OHSS. Among infertile women undergoing IVF treatment at risk of developing OHSS, 206 were enrolled in this study. The subjects were randomly allocated into two groups, i.e. the study group (n = 100) receiving cabergoline beginning on the day of human chorionic gonadotrophin (HCG) injection and the control group (n = 100) receiving cabergoline starting on the day of oocyte retrieval. Oocyte metaphase-II rate, fertilization rate, clinical outcome and incidence of severe OHSS were compared between the two groups. There were no significant differences in oocyte metaphase-II rate (0.86 ± 0.16 versus 0.85 ± 0.15) or fertilization rate (0.79 ± 0.22 versus 0.76 ± 0.20) or in the incidence of OHSS between two groups. Similarly, there were no significant differences in implantation or clinical pregnancy rate between the two groups. Cabergoline can be administered as soon as HCG injection to prevent early OHSS, without adverse effects on oocyte maturation, fertilization rate and clinical outcome. Cabergoline, a dopamine receptor-2 agonist, is suggested to prevent ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation. Nevertheless, the most suitable timing of cabergoline administration has not yet been studied. The aim of this study was to evaluate the influence of different timing of cabergoline administration on final oocyte maturation, fertilization rate and clinical outcome among patients at risk of developing OHSS. Among infertile women undergoing IVF treatment at risk of developing OHSS, 206 were enrolled in this study. The subjects were randomly allocated into two groups, i.e. the study group (n = 100) receiving cabergoline beginning on the day of human chorionic gonadotrophin (HCG) injection and the control group (n = 100) receiving cabergoline starting on the day of oocyte retrieval. Oocyte metaphase II rate, fertilization rate, clinical outcome and incidence of severe OHSS were compared between the two groups. There were no significant differences in oocyte metaphase II rate (0.86 ± 0.16 versus 0.85 ± 0.15) or fertilization rate (0.79 ± 0.22 versus 0.76 ± 0.20) or in the incidence of OHSS (3/100 versus 1/100) between the control and study groups. Similarly, there were no significant differences in implantation rate (36.6{\%} versus 34.0{\%}) or clinical pregnancy rate (54.0{\%} versus 51.0{\%}) between the two groups. Among women at high risk of OHSS, cabergoline can be administered as soon as the HCG injection to prevent early OHSS, without adverse effects on oocyte maturation, fertilization rate and clinical outcome.",
keywords = "cabergoline, fertilization rate, metaphase-II rate, oocyte maturation, ovarian hyperstimulation syndrome, pregnancy rate",
author = "Seow, {Kok Min} and Lin, {Yu Hung} and Bai, {Chyi Huey} and Chen, {Heng Ju} and Hsieh, {Bih Chwen} and Huang, {Lee Wen} and Tzeng, {Chii Ruey} and Hwang, {Jiann Loong}",
year = "2013",
doi = "10.1016/j.rbmo.2013.03.002",
language = "English",
volume = "26",
pages = "562--568",
journal = "Reproductive BioMedicine Online",
issn = "1472-6483",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Clinical outcome according to timing of cabergoline initiation for prevention of OHSS

T2 - A randomized controlled trial

AU - Seow, Kok Min

AU - Lin, Yu Hung

AU - Bai, Chyi Huey

AU - Chen, Heng Ju

AU - Hsieh, Bih Chwen

AU - Huang, Lee Wen

AU - Tzeng, Chii Ruey

AU - Hwang, Jiann Loong

PY - 2013

Y1 - 2013

N2 - Cabergoline, a dopamine receptor-2 agonist, is suggested to prevent ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation. The aim of this study was to evaluate the influence of different timing of cabergoline administration on clinical outcome among patients at risk of developing OHSS. Among infertile women undergoing IVF treatment at risk of developing OHSS, 206 were enrolled in this study. The subjects were randomly allocated into two groups, i.e. the study group (n = 100) receiving cabergoline beginning on the day of human chorionic gonadotrophin (HCG) injection and the control group (n = 100) receiving cabergoline starting on the day of oocyte retrieval. Oocyte metaphase-II rate, fertilization rate, clinical outcome and incidence of severe OHSS were compared between the two groups. There were no significant differences in oocyte metaphase-II rate (0.86 ± 0.16 versus 0.85 ± 0.15) or fertilization rate (0.79 ± 0.22 versus 0.76 ± 0.20) or in the incidence of OHSS between two groups. Similarly, there were no significant differences in implantation or clinical pregnancy rate between the two groups. Cabergoline can be administered as soon as HCG injection to prevent early OHSS, without adverse effects on oocyte maturation, fertilization rate and clinical outcome. Cabergoline, a dopamine receptor-2 agonist, is suggested to prevent ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation. Nevertheless, the most suitable timing of cabergoline administration has not yet been studied. The aim of this study was to evaluate the influence of different timing of cabergoline administration on final oocyte maturation, fertilization rate and clinical outcome among patients at risk of developing OHSS. Among infertile women undergoing IVF treatment at risk of developing OHSS, 206 were enrolled in this study. The subjects were randomly allocated into two groups, i.e. the study group (n = 100) receiving cabergoline beginning on the day of human chorionic gonadotrophin (HCG) injection and the control group (n = 100) receiving cabergoline starting on the day of oocyte retrieval. Oocyte metaphase II rate, fertilization rate, clinical outcome and incidence of severe OHSS were compared between the two groups. There were no significant differences in oocyte metaphase II rate (0.86 ± 0.16 versus 0.85 ± 0.15) or fertilization rate (0.79 ± 0.22 versus 0.76 ± 0.20) or in the incidence of OHSS (3/100 versus 1/100) between the control and study groups. Similarly, there were no significant differences in implantation rate (36.6% versus 34.0%) or clinical pregnancy rate (54.0% versus 51.0%) between the two groups. Among women at high risk of OHSS, cabergoline can be administered as soon as the HCG injection to prevent early OHSS, without adverse effects on oocyte maturation, fertilization rate and clinical outcome.

AB - Cabergoline, a dopamine receptor-2 agonist, is suggested to prevent ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation. The aim of this study was to evaluate the influence of different timing of cabergoline administration on clinical outcome among patients at risk of developing OHSS. Among infertile women undergoing IVF treatment at risk of developing OHSS, 206 were enrolled in this study. The subjects were randomly allocated into two groups, i.e. the study group (n = 100) receiving cabergoline beginning on the day of human chorionic gonadotrophin (HCG) injection and the control group (n = 100) receiving cabergoline starting on the day of oocyte retrieval. Oocyte metaphase-II rate, fertilization rate, clinical outcome and incidence of severe OHSS were compared between the two groups. There were no significant differences in oocyte metaphase-II rate (0.86 ± 0.16 versus 0.85 ± 0.15) or fertilization rate (0.79 ± 0.22 versus 0.76 ± 0.20) or in the incidence of OHSS between two groups. Similarly, there were no significant differences in implantation or clinical pregnancy rate between the two groups. Cabergoline can be administered as soon as HCG injection to prevent early OHSS, without adverse effects on oocyte maturation, fertilization rate and clinical outcome. Cabergoline, a dopamine receptor-2 agonist, is suggested to prevent ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation. Nevertheless, the most suitable timing of cabergoline administration has not yet been studied. The aim of this study was to evaluate the influence of different timing of cabergoline administration on final oocyte maturation, fertilization rate and clinical outcome among patients at risk of developing OHSS. Among infertile women undergoing IVF treatment at risk of developing OHSS, 206 were enrolled in this study. The subjects were randomly allocated into two groups, i.e. the study group (n = 100) receiving cabergoline beginning on the day of human chorionic gonadotrophin (HCG) injection and the control group (n = 100) receiving cabergoline starting on the day of oocyte retrieval. Oocyte metaphase II rate, fertilization rate, clinical outcome and incidence of severe OHSS were compared between the two groups. There were no significant differences in oocyte metaphase II rate (0.86 ± 0.16 versus 0.85 ± 0.15) or fertilization rate (0.79 ± 0.22 versus 0.76 ± 0.20) or in the incidence of OHSS (3/100 versus 1/100) between the control and study groups. Similarly, there were no significant differences in implantation rate (36.6% versus 34.0%) or clinical pregnancy rate (54.0% versus 51.0%) between the two groups. Among women at high risk of OHSS, cabergoline can be administered as soon as the HCG injection to prevent early OHSS, without adverse effects on oocyte maturation, fertilization rate and clinical outcome.

KW - cabergoline

KW - fertilization rate

KW - metaphase-II rate

KW - oocyte maturation

KW - ovarian hyperstimulation syndrome

KW - pregnancy rate

UR - http://www.scopus.com/inward/record.url?scp=84878536642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878536642&partnerID=8YFLogxK

U2 - 10.1016/j.rbmo.2013.03.002

DO - 10.1016/j.rbmo.2013.03.002

M3 - Article

C2 - 23608246

AN - SCOPUS:84878536642

VL - 26

SP - 562

EP - 568

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

SN - 1472-6483

IS - 6

ER -